Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of
Animals
Cell Line, Tumor
Chelating Agents
/ chemistry
Copper Radioisotopes
/ chemistry
Fluorodeoxyglucose F18
Heterocyclic Compounds, 2-Ring
/ chemistry
Heterografts
Humans
Injections, Intravenous
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Transplantation
Neoplasms
/ diagnostic imaging
Organophosphonates
/ chemistry
Positron-Emission Tomography
/ methods
Receptor, ErbB-2
/ metabolism
Tissue Distribution
Trastuzumab
/ chemistry
Urokinase-Type Plasminogen Activator
/ administration & dosage
cancer imaging
clearance enhancement
imaging contrast
immuno-positron emission tomography
trastuzumab
urokinase
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 03 2019
04 03 2019
Historique:
pubmed:
12
1
2019
medline:
18
12
2019
entrez:
12
1
2019
Statut:
ppublish
Résumé
Immuno-positron emission tomography (immuno-PET) is expected to improve the specificity of small chemical tracers such as
Identifiants
pubmed: 30633529
doi: 10.1021/acs.molpharmaceut.8b01052
doi:
Substances chimiques
1,4,8,11-tetraazacyclotetradecane-1-(methanephosphonic acid)-8-(methane carboxylic acid)
0
Chelating Agents
0
Copper Radioisotopes
0
Heterocyclic Compounds, 2-Ring
0
Organophosphonates
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Urokinase-Type Plasminogen Activator
EC 3.4.21.73
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM